for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Auris Medical Holding Ltd

EARS.OQ

Latest Trade

1.07USD

Change

-0.02(-1.83%)

Volume

33,975

Today's Range

1.06

 - 

1.18

52 Week Range

0.65

 - 

3.18

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.09
Open
1.07
Volume
33,975
3M AVG Volume
6.17
Today's High
1.18
Today's Low
1.06
52 Week High
3.18
52 Week Low
0.65
Shares Out (MIL)
4.61
Market Cap (MIL)
4.79
Forward P/E
-0.39
Dividend (Yield %)
--

Latest Developments

More

Auris Medical Announces Positive Top-Line Data From Am-201 Phase 1B Study In Antipsychotic-Induced Weight Gain

Auris Medical Says Phase 2 Trial With Intranasal Betahistine For Treatment Of Acute Vertigo Progressing Towards Interim Analysis

Auris Medical Says Outbreak Has Delayed Enrollment Into Phase 2 Trial With AM-125

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Auris Medical Holding Ltd

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.

Industry

Biotechnology & Drugs

Contact Info

Bahnhofstrasse 21

ZUG, ZUG

6300

Switzerland

+41.61.2011350

https://aurismedical.com/

Key Stats

EPS (CHF)

2018

-14.400

2019

-2.280

2020(E)

-2.473
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.65
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-108.17
Return on Equity (TTM)
-69.43

Latest News

Latest News

BRIEF-Auris Medical Provides Q1 Loss Per Share CHF 0.30

* AURIS MEDICAL PROVIDES BUSINESS AND STRATEGY UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Auris Medical Receives Positive Scientific Advice From EMA On Development Plan And Regulatory Pathway For AM-111

* AURIS MEDICAL RECEIVES POSITIVE SCIENTIFIC ADVICE FROM EMA ON DEVELOPMENT PLAN AND REGULATORY PATHWAY FOR AM-111

BRIEF-Auris Medical Announces Early Repayment Of Part Of Its Loan Facility

* AURIS MEDICAL ANNOUNCES EARLY REPAYMENT OF PART OF ITS LOAN FACILITY

BRIEF-Thomas Meyer Reports 12.6 Pct Stake In Auris Medical As Of March 29

* THOMAS MEYER REPORTS 12.6 PCT STAKE IN AURIS MEDICAL HOLDING AG AS OF MARCH 29, 2018 - SEC FILING Source text: (https://bit.ly/2uJaqwA) Further company coverage:

BRIEF-Auris Regains Compliance With Nasdaq's Minimum Bid Price Requirement

* AURIS REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT Source text for Eikon: Further company coverage:

BRIEF-Auris Medical Q4 Loss Per Share CHF 0.10

* AURIS MEDICAL PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Auris Medical Holding AG - Shareholders Approved Merger Between Co And Auris Medical Newco - SEC Filing

* AURIS MEDICAL HOLDING AG - ON MARCH 12, AT THE GENERAL MEETING, SHAREHOLDERS APPROVED MERGER BETWEEN CO AND AURIS MEDICAL NEWCO - SEC FILING

BRIEF-Auris Medical Provides Business Update

* AURIS MEDICAL HOLDING AG - PRELIMINARY TOP-LINE DATA FROM TACTT3 TRIAL INDICATE THAT STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT

BRIEF-Auris Medical Holding AG Files For Resale Of Up To 7.5 Mln Common Shares Issuable Upon Exercise Of Certain Outstanding Warrants

* AURIS MEDICAL HOLDING AG FILES FOR RESALE OF UP TO 7.5 MILLION COMMON SHARES ISSUABLE UPON EXERCISE OF CERTAIN OUTSTANDING WARRANTS - SEC FILING Source text: [http://bit.ly/2BPfTod] Further company coverage:

BRIEF-Auris Medical Reports New Data Highlighting Superior Bioavailability Of AM-125

* AURIS MEDICAL REPORTS NEW DATA HIGHLIGHTING SUPERIOR BIOAVAILABILITY OF AM-125 COMPARED TO ORAL BETAHISTINE

BRIEF-Auris Medical Announces Pricing Of $5.5 Mln Registered Direct Offering

* AURIS MEDICAL ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT OFFERING

BRIEF-Auris Medical Announces Further Results From Healos Phase 3 Trial

* AURIS MEDICAL HOLDING AG SAYS ANNOUNCED FURTHER CLINICAL RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL, PROVIDES UPDATE ON AM-111 DEVELOPMENT PROGRAM

UPDATE 2-Auris Medical shares plunge as deafness drug trial scrapped

* Shares plummet >50 pct to $0.38 (Adds background, details on Auris' pipeline; updates shares)

BRIEF-Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness

* AURIS MEDICAL HOLDING AG SAYS ANNOUNCED TOP-LINE RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL OF AM-111 IN SEVERE TO PROFOUND SUDDEN DEAFNESS

Auris Medical to abandon hearing-loss drug trial

Auris Medical Holding AG said on Tuesday it would terminate a late-stage study testing its drug to treat sudden deafness after the company's lead drug failed to improve hearing ability in patients in another study.

BRIEF-Auris Medical Reports Q3 Loss Per Share CHF 0.14

* AURIS MEDICAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Auris Medical Holding AG files for resale of up to 7.2 mln common shares

* Auris Medical Holding AG files for resale of up to 7.2 million common shares by selling shareholder, LPC Capital Fund Llc - SEC Filing Source text: (http://bit.ly/2ggfWjL) Further company coverage:

BRIEF-Auris Medical announces share purchase agreements with Lincoln Park Capital Fund

* Auris Medical announces share purchase agreements with Lincoln Park Capital Fund, Llc

BRIEF-Auris Medical announces transfer to Nasdaq capital market

* Auris Medical Holding AG - co's shares will continue to trade uninterrupted under symbol "EARS."

BRIEF-Auris Medical provides board of directors update

* Auris Medical Holding Ag - announced resignation of antoine papiernik as a member of board of directors due to disagreement with board

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up